Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Monoclonal Antibody
99%
Chemotherapy
98%
Phase I Trials
90%
Disease
86%
Idiopathic Thrombocytopenic Purpura
85%
Nonhodgkin Lymphoma
75%
Malignant Neoplasm
67%
Adverse Event
66%
Clinical Trial
61%
Pharmacokinetics
60%
Non Small Cell Lung Cancer
54%
Breast Cancer
52%
Carboplatin
52%
Overall Survival
52%
Solid Malignant Neoplasm
50%
Rituximab
48%
Cetuximab
45%
Eltrombopag
45%
Bevacizumab
45%
Iodine-131
42%
Docetaxel
42%
Progression Free Survival
41%
Phase II Trials
40%
Maximum Tolerated Dose
39%
Gemcitabine
38%
Paclitaxel
37%
Antitumor Activity
36%
Prostate Cancer
35%
Metastatic Breast Cancer
32%
Doxorubicin
32%
Metastatic Colorectal Cancer
30%
Placebo
29%
Castration Resistant Prostate Cancer
27%
Receptor
27%
Thrombocytopenia
23%
Subcutaneous Injection
23%
Neutropenia
22%
Metastatic Melanoma
22%
Edrecolomab
22%
Ibritumomab Tiuxetan
22%
Prednisone
21%
Combination Therapy
21%
Carcinoembryonic Antigen
20%
Abiraterone Acetate
20%
Androgen
20%
Immunoglobulin
19%
Epidermal Growth Factor Receptor
19%
Adenocarcinoma
19%
Mouse
19%
Medicine and Dentistry
Breast Cancer
98%
Idiopathic Thrombocytopenic Purpura
67%
Neoplasm
51%
Malignant Neoplasm
46%
Platelet
42%
Eltrombopag
37%
Monoclonal Antibody
33%
Clinical Trial
32%
Diseases
32%
Bevacizumab
30%
Non-Hodgkin Lymphoma
26%
Low Drug Dose
25%
Awareness
24%
Low and Middle Income Countries
24%
Arm
23%
Diagnosis
23%
Iodine 131
22%
Metastatic Colorectal Cancer
22%
B Cell
22%
Adverse Event
21%
Triple Negative Breast Cancer
18%
COVID-19
17%
Progression Free Survival
17%
Placebo
17%
Overall Survival
17%
CD20
15%
Antibody-Drug Conjugate
15%
Glembatumumab Vedotin
15%
Metastatic Melanoma
15%
Glycoprotein
15%
Tositumomab
15%
Veltuzumab
15%
Arsenic Trioxide
15%
Phase I Trials
15%
Solid Malignant Neoplasm
15%
Letrozole
15%
Postmenopause
15%
Radiation Therapy
15%
Cancer
15%
Carboplatin
15%
Gemcitabine
15%
Bendamustine
15%
Clinician
13%
Prevalence
13%
Chemotherapy Regimens
12%
Infusion
12%
Immunoglobulin
12%
Monocyte
12%
Receptor
12%
Thrombocytopenia
12%
Immunology and Microbiology
Platelet
54%
Monoclonal Antibody
53%
Monocyte
46%
Immune Response
44%
Idiopathic Thrombocytopenic Purpura
37%
Pharmacokinetics
32%
Arm
25%
Glycoprotein
22%
Iodine-131
22%
Antibody Response
22%
Intravenous Immunoglobulin
21%
Monospecific Antibody
19%
T Cell
18%
Fc Receptor
17%
Human Immunoglobulin
17%
Mouse
16%
Rituximab
15%
Antiidiotypic Antibody
15%
Glembatumumab Vedotin
15%
Antibody Drug Conjugate
15%
Carcinoembryonic Antigen
15%
Microbiome
15%
Edrecolomab
15%
Interferon Type I
15%
Thrombocyte Membrane
14%
Murine
13%
Blood Plasma
13%
Vaccine Efficacy
12%
B Cell
12%
Maximum Tolerated Dose
11%
Platelet Count
11%
Blood Level
11%
Tumor Antigen
11%
Interleukin 2 Receptor
11%
CD20
10%
Chimeric Antibody
10%
Low Drug Dose
10%
Plasma Half Life
9%
CD16
9%
Immunoglobulin G4
9%
Biological Product
9%
Cyclophosphamide
8%
Immunoglobulin G1
8%
Lupus Erythematosus
8%
Surface Property
8%
Antigen Expression
8%
Tigatuzumab
7%
Veltuzumab
7%
Interferon
7%
Trastuzumab
7%